Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.Donate to our crowdfunder
To ask the Secretary of State for Health who authorised the signing of the contract between the National Institute of Clinical Excellence (NICE) and Southampton Technology Assessment Centre (SHTAC) that provides that the cost-effectiveness model prepared by SHTAC for NICE for consideration in the technology appraisal of donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's disease cannot be disclosed under the Freedom of Information Act 2000; and if she will make a statement.
The contract, with the University of Southampton, for technology assessment review reports was authorised by the Department's director of research and development (R&D) and signed by an official on behalf of the Secretary of State for Health. It is a standard Departmental R&D contract, which invests intellectual property with the research contractor. Details of the relevant intellectual property policy is available on the Department's website at: www.dh.gov.uk/PolicyAndGuidance/ResearchAndDevelopment.